Tango Therapeutics(NASDAQ) TNGX

Tango Therapeutics, Inc. makes new drugs to treat cancer. These medicines target genetic changes that drive tumor growth. They aim to kill cancer cells while sparing healthy ones.

Fighting Cancer With Precision

• Vopimetostat: A selective inhibitor designed to block specific proteins in tumors outside the brain.
• TNG456: A brain-penetrant therapy focused on treating aggressive tumors like glioblastoma.
• USP1 Inhibitor: A candidate targeting cancers with specific BRCA1 or BRCA2 genetic mutations.
• Target 3: A discovery program addressing cancers characterized by STK11 genetic alterations.

Strategic Steps and Clinical Progress

• Partnered with Erasca in March 2026 to evaluate drug combinations for cancer treatment.
• Raised $651.4 million in net proceeds through a public stock offering in June 2026.
• Concluded the research portion of a multiyear collaboration with Gilead Sciences in August 2025.
• Treated the first patient in a combination clinical trial in June 2025.

What Makes Tango Stand Out

The company uses a discovery platform to identify synthetic lethality targets. This method identifies gene pairs where losing both leads to cell death, allowing for highly targeted cancer treatments.

The Recent Financial Record

• Cash and marketable securities totaled $1.0 billion as of June 30, 2026.
• Net loss reached $100.9 million for the six-month period ended June 30, 2026.
• Research and development expenses rose to $70.7 million for the first half of 2026.
• Collaboration revenue was $0 for the six-month period ended June 30, 2026.

Evolution of the Business

Tango has narrowed its focus to its most promising clinical programs while securing the capital needed for late-stage trials. The company continues to transition from early discovery to the development of targeted oncology medicines.